摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(1-acetylpiperidin-4-yl)-6-[[2-(trifluoromethoxy)phenyl]methyl]-5H-pyrazolo[3,4-d]pyrimidin-4-one | 1189768-63-5

中文名称
——
中文别名
——
英文名称
1-(1-acetylpiperidin-4-yl)-6-[[2-(trifluoromethoxy)phenyl]methyl]-5H-pyrazolo[3,4-d]pyrimidin-4-one
英文别名
——
1-(1-acetylpiperidin-4-yl)-6-[[2-(trifluoromethoxy)phenyl]methyl]-5H-pyrazolo[3,4-d]pyrimidin-4-one化学式
CAS
1189768-63-5
化学式
C20H20F3N5O3
mdl
——
分子量
435.406
InChiKey
VDEYKAQHCILSJC-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.1
  • 重原子数:
    31
  • 可旋转键数:
    4
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.4
  • 拓扑面积:
    88.8
  • 氢给体数:
    1
  • 氢受体数:
    8

文献信息

  • [EN] 1-HETEROCYCLYL-1,5-DIHYDRO-PYRAZOLO[3,4-D] PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A MODULATORS<br/>[FR] DÉRIVÉS DE 1-HÉTÉROCYCLYL-1,5-DIHYDRO-PYRAZOLO[3,4-D]PYRIMIDIN-4-ONE ET LEURS UTILISATIONS À TITRE DE MODULATEURS DE PDE9A
    申请人:BOEHRINGER INGELHEIM INT
    公开号:WO2009121919A1
    公开(公告)日:2009-10-08
    The invention relates to novel 1,6-disubstituted pyrazolopyrimidinones, Formula (I) with Hc is a mono-, bi- or tricyclic heterocyclyl group, the ring members of which are carbon atoms and at least 1, preferably 1, 2 or 3, heteroatom(s), which are selected from the group of nitrogen, oxygen and sulphur, which is in the form of -S(O)r - with r being 0, 1 or 2, and - said heterocyclyl group is or comprises 1 non-aromatic, saturated, or partly unsaturated monocyclic ring which comprises at least 1 heteroatom as ring member and - said heterocyclyl group is bound to the scaffold by said 1 non- aromatic, saturated, or partly unsaturated monocyclic ring which comprises at least 1 heteroatom as ring member. According to one aspect of the invention the new compounds are for the manufacture of medicaments, in particular medicaments for the treatment of conditions concerning deficits in perception, concentration, learning or memory. The new compounds are also for the manufacture of medicaments for the treatment of Alzheimer's disease.
    该发明涉及新型1,6-二取代吡唑嘧啶酮,化学式(I),其中Hc是一个单环、双环或三环杂环基团,其环成员为碳原子和至少1个,优选1个、2个或3个来自氮、氧和的杂原子,其以-S(O)r-的形式存在,其中r为0、1或2,所述杂环基团是或包括1个非芳香、饱和或部分不饱和的单环环,其中至少包含1个杂原子作为环成员,所述杂环基团通过所述至少包含1个杂原子作为环成员的非芳香、饱和或部分不饱和的单环环与支架相结合。根据该发明的一个方面,新化合物用于制造药物,特别是用于治疗感知、注意力、学习或记忆缺陷相关疾病的药物。新化合物还用于制造治疗阿尔茨海默病的药物。
  • 1-HETEROCYCLYL-1,5-DIHYDRO-PYRAZOLO[3,4-D] PYRIMIDIN-4-ONE DERIVATES AND THEIR USE AS PDE9A MODULATORS
    申请人:Giovannini Riccardo
    公开号:US20110184000A1
    公开(公告)日:2011-07-28
    The invention relates to novel 1,6-disubstituted pyrazolopyrimidinones, Formula (I) with is a mono-, bi- or tri-cyclic heterocyclyl group, the ring members of which are carbon atoms and at least 1, preferably 1, 2 or 3, heteroatom(s), which are selected from the group of nitrogen, oxygen and sulphur, which is in the form of —S(O) r — with r being 0, 1 or 2, and—said heterocyclyl group is or comprises 1 non-aromatic, saturated, or partly unsaturated monocyclic ring which comprises at least 1 heteroatom as ring member and—said heterocyclyl group is bound to the scaffold by said 1 non-aromatic, saturated, or partly unsaturated monocyclic ring which comprises at least 1 heteroatom as ring member. According to one aspect of the invention the new compounds are for the manufacture of medicaments, in particular medicaments for the treatment of conditions concerning deficits in perception, concentration, learning or memory. The new compounds are also for the manufacture of medicaments for the treatment of Alzheimer's disease.
    本发明涉及一种新型的1,6-二取代吡唑嘧啶酮(Formula (I)),其中为单、双或三环杂环基,其环成员为碳原子,至少1个,优选1、2或3个杂原子,所述杂原子选自氮、氧和的群体,并以—S(O)r—的形式出现,其中r为0、1或2,所述杂环基是或包含1个非芳香、饱和或部分不饱和的单环环,其中至少包含1个杂原子作为环成员,并且所述杂环基通过所述1个非芳香、饱和或部分不饱和的单环环,其中至少包含1个杂原子作为环成员,与支架结合。根据本发明的一方面,新化合物用于制造药物,特别是用于治疗感知、注意力、学习或记忆缺陷的药物。新化合物也用于制造治疗阿尔茨海默病的药物。
  • NEW COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS
    申请人:GIOVANNINI Riccardo
    公开号:US20110082137A1
    公开(公告)日:2011-04-07
    The invention relates to novel 1,6-disubstituted pyrazolopyrimidinones of formula (I), in which Hc is a tetrahydropyranyl-group and R 1 is the group V—W−*, whereby V and W independently of each other may be an aryl group or an heteroaryl group, which independently of each other may optionally be substituted. According to one aspect of the invention the new compounds are for use as medicaments or for the manufacture of medicaments, in particular medicaments for the treatment of conditions concerning deficits in perception, concentration, learning or memory. The new compounds are also for the manufacture of medicaments and/or for use in the treatment of e.g. Alzheimer's disease, in particular for cognitive impairment associated with Alzheimer's disease.
    本发明涉及一种新型的1,6-二取代吡唑嘧啶酮化合物,其化学式为(I),其中Hc为四氢吡喃基团,R1为V-W−*基团,其中V和W各自独立地可以是芳基基团或杂环基团,可以选择地进行取代。根据本发明的一个方面,这些新化合物可用作药物或制药用途,特别是用于治疗与感知、注意力、学习或记忆缺陷有关的疾病。这些新化合物还可用于制药或用于治疗例如阿尔茨海默病等疾病,特别是用于与阿尔茨海默病相关的认知障碍的治疗。
  • 1-HETEROCYCLYL-1,5-DIHYDRO-PYRAZOLO[3,4-D] PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A MODULATORS
    申请人:GIOVANNINI Riccardo
    公开号:US20140073641A1
    公开(公告)日:2014-03-13
    The invention relates to novel 1,6-disubstituted pyrazolopyrimidinones, wherein i.) the nitrogen atom of the pyrazolo-group that is next to the pyrimidino-group is attached to a non-aromatic, organic heterocycle having at least one ring hetero atom selected from O, N and S and ii.) to the C-atom between the two nitrogen atoms of the pyrimidinone-ring a second substituent is bound via an optionally substituted methylene-bridge. According to one aspect of the invention the new compounds are for the manufacture of medicaments, in particular medicaments for the treatment of conditions concerning deficits in perception, concentration, learning or memory. The new compounds are also for the manufacture of medicaments for the treatment of Alzheimer's disease.
    本发明涉及新型1,6-二取代吡唑嘧啶酮,其中i)紧邻嘧啶基的吡唑环上的氮原子连接到至少具有一个O、N和S中的环异构原子的非芳香性有机杂环上,ii)通过可选取代的亚甲基桥连接到嘧啶酮环的两个氮原子之间的C原子上的第二个取代基。根据本发明的一个方面,新化合物用于制造药物,特别是用于治疗感知、注意力、学习或记忆缺陷的药物。新化合物还用于制造治疗阿尔茨海默病的药物。
  • 1-HETEROCYCLYL-1,5-DIHYDRO-PYRAZOLO[3,4-D]PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A MODULATORS
    申请人:Boehringer Ingelheim International GmbH
    公开号:EP2300478B1
    公开(公告)日:2016-03-23
查看更多

同类化合物

阿扎次黄嘌呤 钠2-氨基-6-甲基-[1,2,4]三唑并[1,5-a]嘧啶-5-醇 苯酚,4-[2-[[7-氨基-2-(2-呋喃基)[1,2,4]三唑并[1,5-a][1,3,5]三嗪-5-基]氨基]乙氧基]- 替格雷洛-d7 替格瑞洛羟基杂质 替格瑞洛杂质R1788033-05-5摩科品牌提供图谱 替格瑞洛杂质K 替格瑞洛杂质J 替格瑞洛杂质H 替格瑞洛杂质F 替格瑞洛杂质85 替格瑞洛杂质27 替格瑞洛杂质 替格瑞洛杂质 替格瑞洛中间体1脱保护杂质 替格瑞洛 曲匹地尔 异亚丙基替卡格雷 布美地尔 唑嘧菌胺 唑嘧磺草胺 吡唑并[1,5-a]嘧啶-7(4H)-酮,2-甲基-6-硝基-,盐钠 去羟基乙氧基替格雷洛 去羟基乙氧基-2,3-O-(二甲基亚甲基)替格雷洛 化合物 T15173 v-三唑并[4,5-d]嘧啶,(3H),3-环戊基-7-偏基硫代- [[[3-(4,7-二氢-7-氧代-1H-1,2,3-三唑并[4,5-d]嘧啶-5-基)-4-丙氧基苯基]氨基]亚甲基]丙二酸二乙酯 [1,2,4]噻唑并[1,5-c]嘧啶-5(6h)-酮 [1,2,4]三氮唑并[1,5-A]嘧啶-2-胺 [1,2,4]三唑并[3,4-f]嘧啶 [1,2,4]三唑并[1,5-a]嘧啶-7-酚,5-壬基- [1,2,4]三唑并[1,5-a]嘧啶-7(1H)-酮,2-甲基-6-硝基-,盐钠 [1,2,4]三唑并[1,5-A]嘧啶-2-羧酸甲酯 [1,2,4]三唑并[1,5-A]嘧啶-2-羧酸 [1,2,4]三唑[1,5,A]嘧啶-7-氨基 [(1R,3S)-3-(5-氨基-7-氯-3H-[1,2,3]三唑并[4,5-d]嘧啶-3-基)环戊基]甲醇 [(1R,3S)-3-(5,7-二氨基-3H-[1,2,3]三唑并[4,5-d]嘧啶-3-基)环戊基]甲醇 N-甲基-1H-1,2,3-三唑并[4,5-d]嘧啶-7-胺 N-(4'-氟丁酰苯)-4-(4-氯苯基)吡啶正离子 N-(2,6-二氯苯基)-5,7-二甲基[1,2,4]三唑并[1,5-a]嘧啶-2-磺酰胺 N-(2,6-二氯-3-甲苯基)-5,7-二甲氧基-[1,2,4]三唑[1,5-a]嘧啶-2-磺酰胺 N-(2,6-二氯-3-甲基苯基)-5,7-二氯-1,2,4-三唑并[1,5-a]吡啶-2-磺酰胺 N-(1,5,6,7-四氢-3,6-二甲基-5,7-二氧代-1,2,4-三唑并[4,3-c]嘧啶-8-基)-乙酰胺 EED抑制剂(EEDINHIBITOR-1) 9H-7,8-二氢-(1,2,3)三唑并(4',5'-4,5)嘧啶并(6,1-b)(1,3)噻嗪-5(3H)-酮 9-乙基-2,4,7,8,9-五氮杂双环[4.3.0]壬-1,3,5,7-四烯-3,5-二胺 8-甲氧基-3-甲基-[1,2,4]三唑并[4,3-C]嘧啶 8-甲基-1,3,7,9-四氮杂双环[4.3.0]壬-2,4,6,8-四烯 8-溴-[1,2,4]三唑并[4,3-c]嘧啶 8-溴-5-(甲硫基)[1,2,4]三唑并[4,3-c]嘧啶